Nebraska voters will decide on Medicaid expansion in November; a medical watchdog has called for a stop to a clinical trial for sepsis treatment; Medicare Advantage insurer Clover Health is expanding its health plans to 6 new markets.
A campaign to get Medicaid expansion on the ballot in Nebraska this November met all of its requirements, giving voters the decision to expand Medicaid to nearly 90,000 individuals. According to The Hill, Insure the Good Life, the ballot initiative committee, obtained 104,477 valid signatures, exceeding the signature requirement by more than 20,000. Nebraska marks the fourth state this year preparing to put Medicaid expansion on the ballot in November.
As the National Institutes of Health continues to enroll patients in a clinical trial of sepsis treatment, medical watchdog Public Citizen is calling for the immediate halt of enrollment. The watchdog is also calling for an investigation into how the study received approval, arguing that it puts patients at risk of serious harm, STAT News reported. In a letter, it says the study's protocol is so "fundamentally flawed" that it will not produce reliable results.
Medicare Advantage (MA) insurer Clover Health announced a significant expansion with plans to enter 6 new markets in 2019. In the coming year, it will be offering its MA plans in El Paso, Texas; Camden, New Jersey; Charleston, South Carolina; Nashville, Tennessee; Philadelphia, Pennsylvania; and Tucson, Arizona. Clover Health also released results showing its technology has an 85% accuracy rate in identifying patients at risk of being admitted to the hospital in the next 28 days.
Telephone Follow-Up on Medicare Patient Surveys Remains Critical
January 16th 2025Including a telephone component in Medicare Consumer Assessment of Healthcare Providers and Systems survey administration continues to be valuable because telephone responses comprise a substantial portion of responses for several underserved groups.
Read More
Quantifying the Altruism Value for a Rare Pediatric Disease: Duchenne Muscular Dystrophy
January 14th 2025Altruism values for treatments of rare, severe pediatric diseases have not been estimated. This study found the altruism value for a hypothetical new Duchenne muscular dystrophy treatment to be $80 per year.
Read More
Health Equity & Access Weekly Roundup: January 11, 2025
January 11th 2025ACA enrollment rate hits a milestone, though IRA subsidies may not extend beyond 2025; network adequacy standards fail to translate into efficient access to mental health care for Medicaid enrollees; research examines racial disparities in postpartum hypertension and vaccine uptake.
Read More